Evidence map›Paper›PMID 34558140›Full record

ArticleJournal of magnetic resonance imaging : JMRI2022

Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.

Je Yeong Sone, Nicholas Hobson, Abhinav Srinath, Sharbel G Romanos, Ying Li, Julián Carrión-Penagos, Abdallah Shkoukani, Agnieszka Stadnik, Kristina Piedad, Rhonda Lightle and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Je Yeong SoneNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.ORCID 0000-0002-6451-4401
Nicholas HobsonNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.ORCID 0000-0001-6034-8795
Abhinav SrinathNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Sharbel G RomanosNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Ying LiNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Julián Carrión-PenagosNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Abdallah ShkoukaniNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Agnieszka StadnikNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Kristina PiedadNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Rhonda LightleNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Thomas MooreNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Dorothy DeBiasseNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Dehua BiNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Robert ShenkarNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.ORCID 0000-0002-1300-6845
Timothy CarrollDepartment of Diagnostic Radiology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Yuan JiDepartment of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.
Romuald GirardNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Issam A AwadNeurovascular Surgery Program, Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
University of Chicago · USChicago Department of Public Health · US

Funding

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)T32HD007009 · NICHD · UNIVERSITY OF CHICAGO · PI NANCY B SCHWARTZ · 1985 to 2026
$13.0M
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) TrialR01NS107887 · NINDS · UNIVERSITY OF CHICAGO · PI AWAD, ISSAM A · 2018 to 2022
$3.9M
Trial Readiness in Cavernous Angiomas with Symptomatic HemorrhageU01NS104157 · NINDS · UNIVERSITY OF CHICAGO · PI AWAD, ISSAM A · 2018 to 2022
$3.8M
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH) - SupplementalR01NS114552 · NINDS · UNIVERSITY OF CHICAGO · PI AWAD, ISSAM A · 2020 to 2024
$3.4M
BIOMARKERS OF BRAIN PERMEABILITY IN HUMAN CEREBRAL CAVERNOUS MALFORMATIONSR21NS087328 · NINDS · UNIVERSITY OF CHICAGO · PI AWAD, ISSAM A · 2014 to 2015
$435k
NICHD NIH HHS T32 HD007009NINDS NIH HHS R01 NS107887NINDS NIH HHS R01 NS114552NINDS NIH HHS R21 NS087328NINDS NIH HHS U01 NS104157
6 · The paper itself

Abstract

backgroundCerebral cavernous angioma (CA) is a capillary vasculopathy affecting more than a million Americans with a small fraction of cases demonstrating lesional bleed or growth with major clinical sequelae. Perfusion and permeability are fundamental features of CA pathophysiology, but their role as prognostic biomarkers is unclear. PURPOSE: To investigate whether perfusion or permeability lesional descriptors derived from dynamic contrast-enhanced quantitative perfusion (DCEQP) magnetic resonance imaging (MRI) can predict subsequent lesional bleed/growth in the year following imaging. STUDY TYPE: Single-site case-controlled study. SUBJECTS: Two hundred and five consecutively enrolled patients (63.4% female). FIELD STRENGTH/SEQUENCE: Three-Tesla/T ASSESSMENT: Prognostic associations with bleed/growth (present or absent) in the following year were assessed in 745 CA lesions evaluated by DCEQP in the 205 patients in relation to lesional descriptors calculated from permeability and perfusion maps. A subgroup of 30 cases also underwent peripheral blood collection at the time of DCEQP scans and assays of plasma levels of soluble CD14, IL-1β, VEGF, and soluble ROBO4 proteins, whose weighted combination had been previously reported in association with future CA bleeding. STATISTICAL TESTS: Mann-Whitney U-test for univariate analyses. Logistic regression models minimizing the Bayesian information criterion (BIC), testing sensitivity and specificity (receiver operating characteristic curves) of weighted combinations of parameters.

resultsThe best prognostic biomarker for lesional bleed or growth included brainstem lesion location, mean lesional permeability, and low-value perfusion cluster mean (BIC = 201.5, sensitivity = 77%, specificity = 72%, P < 0.05). Adding a previously published prognostic plasma protein biomarker improved the performance of the imaging model (sensitivity = 100%, specificity = 88%, P < 0.05). DATA

conclusionA combination of MRI-based descriptors reflecting higher lesional permeability and lower perfusion cluster may potentially predict future bleed/growth in CAs. The sensitivity and specificity of the prognostic imaging biomarker can be enhanced when combined with brainstem lesion location and a plasma protein biomarker of CA hemorrhage. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY: Stage 5.

Indexed as

Hemangioma, CavernousMagnetic Resonance ImagingBayes TheoremBiomarkersContrast MediaFemaleHemorrhageHumansMalePerfusionPermeabilityBiomarkersContrast Mediacavernous angiomagrowthhemorrhagemagnetic resonance imagingperfusionpermeability

Identifiers

PMID34558140
PMCPMC8942875
OpenAlexW3200188994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.